Unknown

Dataset Information

0

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.


ABSTRACT: To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of ?4-integrin (CD49d).Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD49d+Th17, and CD49d+Treg, respectively).Natalizumab treatment increased CD49d ratios, CD49d+Th1/CD49d+Treg, and CD49d+Th17/CD49d+Treg. This indicates larger reduction of the CD49d+ population in Treg cells than in Th1 or Th17 cells. The CD49d ratios of 2 patients who experienced exacerbation during natalizumab treatment were remarkably higher than those of the other natalizumab-treated patients. Natalizumab treatment increased the expression of TBX21, RORC, interferon (IFN)-?, and interleukin (IL)-17A, and decreased the expression of FOXP3 in CD49d+ memory CD4 T cells. Natalizumab treatment also increased the amount of IFN-? and IL-17A secreted by CD49d+ memory CD4 T cells.The reduction rate of the CD49d+ population in Treg cells was larger than that in Th1 or Th17 cells. Although the large reduction in CD49d+ population is beneficial for MS, the proinflammatory state of residual CD49d+ cells might, in part, explain the presence of disease activity under natalizumab treatment.

SUBMITTER: Kimura K 

PROVIDER: S-EPMC4784802 | biostudies-other | 2016 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.

Kimura Kimitoshi K   Nakamura Masakazu M   Sato Wakiro W   Okamoto Tomoko T   Araki Manabu M   Lin Youwei Y   Murata Miho M   Takahashi Ryosuke R   Yamamura Takashi T  

Neurology(R) neuroimmunology & neuroinflammation 20160303 2


<h4>Objective</h4>To compare effects of natalizumab on inflammatory and regulatory T cells with regard to expression of α4-integrin (CD49d).<h4>Methods</h4>Twenty-seven natalizumab-naive and 8 natalizumab-treated patients with multiple sclerosis (MS), 7 patients with neuromyelitis optica (NMO) or NMO spectrum disorder, and 8 healthy controls were included. The positive rate of CD49d was analyzed and compared among T helper 1 (Th1), T helper 17 (Th17), and regulatory T (Treg) cells (CD49d+Th1, CD  ...[more]

Similar Datasets

| S-EPMC8573181 | biostudies-literature
| S-EPMC3858305 | biostudies-literature
| S-EPMC6389745 | biostudies-literature
| S-EPMC4628051 | biostudies-literature
| S-EPMC3557363 | biostudies-literature
| S-EPMC4299884 | biostudies-other
| S-EPMC7480919 | biostudies-literature
| S-EPMC3302200 | biostudies-other
| S-EPMC5497532 | biostudies-other
| S-EPMC8013024 | biostudies-literature